Analysts Set Icon Plc (NASDAQ:ICLR) PT at $178.75

Shares of Icon Plc (NASDAQ:ICLR) have received an average recommendation of “Hold” from the twelve ratings firms that are presently covering the stock, MarketBeat reports. Seven research analysts have rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $178.75.

Several equities research analysts have recently commented on ICLR shares. SunTrust Banks downgraded Icon from a “buy” rating to a “hold” rating and upped their target price for the company from $170.00 to $182.00 in a report on Monday, January 27th. Mizuho reaffirmed a “buy” rating and set a $194.00 target price (up from $179.00) on shares of Icon in a report on Thursday, February 20th. Citigroup started coverage on Icon in a report on Monday, January 6th. They set a “neutral” rating and a $185.00 target price for the company. Zacks Investment Research downgraded Icon from a “buy” rating to a “hold” rating in a report on Wednesday, January 29th. Finally, Barclays upped their target price on Icon from $168.00 to $182.00 and gave the company an “equal weight” rating in a report on Thursday, February 20th.

Shares of Icon stock traded down $0.73 during trading on Friday, hitting $159.73. The stock had a trading volume of 246,026 shares, compared to its average volume of 218,421. The company has a debt-to-equity ratio of 0.28, a current ratio of 2.03 and a quick ratio of 2.03. The firm has a market cap of $8.62 billion, a P/E ratio of 23.49, a PEG ratio of 1.85 and a beta of 0.77. The business has a fifty day moving average of $171.76 and a two-hundred day moving average of $159.20. Icon has a fifty-two week low of $127.58 and a fifty-two week high of $178.99.

Icon (NASDAQ:ICLR) last announced its quarterly earnings data on Wednesday, February 19th. The medical research company reported $1.83 earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of $1.83. The business had revenue of $725.40 million during the quarter, compared to analyst estimates of $734.13 million. Icon had a return on equity of 25.00% and a net margin of 13.33%. The company’s revenue was up 6.8% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.62 earnings per share. As a group, research analysts forecast that Icon will post 7.74 earnings per share for the current year.

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Investec Asset Management LTD acquired a new position in Icon during the fourth quarter valued at $113,144,000. Comgest Global Investors S.A.S. raised its position in Icon by 51.7% during the third quarter. Comgest Global Investors S.A.S. now owns 1,524,903 shares of the medical research company’s stock valued at $224,680,000 after buying an additional 519,534 shares during the period. SPF Beheer BV acquired a new position in Icon during the third quarter valued at $76,360,000. WCM Investment Management LLC raised its position in Icon by 6.0% during the third quarter. WCM Investment Management LLC now owns 3,595,030 shares of the medical research company’s stock valued at $529,691,000 after buying an additional 203,734 shares during the period. Finally, Massachusetts Financial Services Co. MA raised its position in Icon by 14.3% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 1,590,967 shares of the medical research company’s stock valued at $274,011,000 after buying an additional 199,267 shares during the period. 84.92% of the stock is owned by institutional investors and hedge funds.

About Icon

ICON Public Limited Company, a clinical research organization, provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries in Ireland, rest of Europe, the United States, and internationally. It specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.

Recommended Story: Mutual Funds

Analyst Recommendations for Icon (NASDAQ:ICLR)

Receive News & Ratings for Icon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon and related companies with MarketBeat.com's FREE daily email newsletter.